-
Track & Monitor
Cell & gene therapy in pharma: vascular disorder gene therapies
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the pharma industry’s vascular disorder gene therapies segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered...
-
Product Insights
Clinical Trials – Precision and Personalized Medicine
This report provides analysis of clinical research involving precision and personalized medicines and identifies trends throughout the years. The terms precision and personalized medicine are often used interchangeably as they refer to similar types of treatment. They both define the stratification of patients within a disease segment using their genomic and phenotypic variations to find targeted therapies. This is an alternative to the traditional process of drug design, which typically follows a one-size-fits all approach. Precision and personalized medicine is...
-
Company Profile
Sangamo Therapeutics Inc – Company Profile
Sangamo Therapeutics Inc (Sangamo), formerly Sangamo BioSciences Inc, is a biotechnology company that focuses on the research, development, and commercialization of engineered DNA-binding protein Zinc Finger Transcription (ZFPs). Its ZFPs candidates are based on its proprietary gene therapy technologies. It is advancing its pipeline candidates for the treatment of HIV/AIDS, hemophilia A and B, hurler syndrome (MPS I), Huntington's disease, Fabry disease, Alzheimer's disease, and many others. Its ZFPs based products are used in various applications such as human therapeutics,...
Add to Basket -
Track & Monitor
Innovation in Pharmaceuticals: Viral vectors
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Viral vectors segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based on...
-
Product Insights
Net Present Value Model: BIVV-003
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model BIVV-003 Drug Details SAR-445136 is under...
-
Product Insights
Net Present Value Model: Isaralgagene Civaparvovec
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Isaralgagene Civaparvovec Drug Details Isaralgagene civaparvovec...
-
Product Insights
Net Present Value Model: TX-200
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model TX-200 Drug Details TX-200 is under...
-
Track & Monitor
Immuno-oncology in Pharmaceuticals: CAR-T cell-based compositions
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s CAR-T cell-based compositions segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered based...
-
Track & Monitor
Immuno-oncology in Pharmaceuticals: Cytotoxic T-cell based cancer immunotherapy
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Cytotoxic T-cell based cancer immunotherapy segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or...
-
Track & Monitor
Immuno-oncology in Pharmaceuticals: Gene therapy delivery using viral vectors
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Gene therapy delivery using viral vectors segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed...